UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 15, 2014

AMICUS THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Registrant’s telephone number, including area code: (609) 662-2000

(Former name or former address if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On October 15, 2014, the Board of Directors of Amicus Therapeutics, Inc. (the “Company”) approved an amendment to the Company’s Cash Deferral Plan (the “Plan”) to provide that the election of each participant to defer compensation under the Plan will terminate at the end of each plan year instead of continuing in effect until amended by such participant (the “Amendment”). Accordingly, pursuant to the Amendment, each participant will be required to file a new election for each year in which the participant wishes to defer receipt of such participant’s compensation.  Additionally, the Amendment provided for other administrative changes to the Plan.

The foregoing summary of the Amendment is qualified in its entirety by reference to Amendment #1 to the Cash Deferral Plan, which is included as Exhibit 10.1 to this current report on Form 8-K.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits:

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

3

EXHIBIT INDEX

4

Exhibit 10.1

AMENDMENT NO. 1

TO THE

AMICUS THERAPEUTICS, INC.

CASH DEFERRAL PLAN

WHEREAS, the Board of Directors (the “Board”) of Amicus Therapeutics, Inc. (the “Company”) have previously approved the Amicus Therapeutics, Inc. Cash Deferral Plan (the “Plan”);

WHEREAS, pursuant to the terms of Plan, the Board is empowered to amend the Plan; and

WHEREAS, in connection with the engagement of a new third party servicer of the Plan, the Board determined to make certain administrative changes to the Plan as set forth in this Amendment #1 to the Plan (the “Amendment”).

NOW THEREFORE, the Plan is amended as follows effective as of the date hereof:

1.              The last sentence Section 4.1.2 is hereby amended and restated, which shall read in its entirety as follows:

“The Election of a Participant shall only be operative for the Plan Year with respect to which such Election is made; accordingly any Election filed for the initial Plan Year shall terminate on December 31, 2014.”

2.              All reference in the Plan’s adoption agreement (the “Adoption Agreement”) to “Principal Life Insurance Company” shall be changed to “ADP, LLC.”

3.              The date on which Participant Deferral Credits are made as provided under Section 2.9 of the Adoption Agreement shall be changed to the last business day of each payroll period during the Plan Year.

4.              Except as specifically provided in and modified by this Amendment, the Plan and the Adoption Agreement are in all other respects hereby ratified and confirmed and references to the Plan and the Adoption Agreement shall be deemed to refer to the Plan and the Adoption Agreement as modified by this Amendment.

To record the adoption of this Amendment #1, to the Amicus Therapeutics, Inc. Cash Deferral Plan, the Company has caused its authorized officer to affix its corporate name this 15th day of October, 2014.

2